8-K: GoodRx Appoints Thomas Chan as Chief Accounting Officer

GoodRx Holdings, Inc. has promoted Thomas Chan to the role of Chief Accounting Officer, effective immediately.

Summary

• Thomas Chan, previously Vice President, Corporate Controller, has been appointed as the new Chief Accounting Officer.
• Mr. Chan has been with GoodRx since October 2020, serving in various financial reporting and accounting leadership roles.
• The appointment includes a compensation package consisting of a $310,000 base salary, a 40% target annual bonus, and equity grants totaling $175,000 in value.
• The equity package comprises $131,250 in Restricted Stock Units (RSUs) and $43,750 in Performance-based Restricted Stock Units (PSUs).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine corporate governance update regarding an internal executive promotion.

Positives

• Internal promotion demonstrates strong succession planning and retention of institutional knowledge.
• Mr. Chan brings extensive experience from his tenure at Deloitte & Touche, LLP prior to joining the company.
• The compensation structure aligns the new officer's interests with long-term shareholder value through performance-based equity vesting.

Negatives

• None identified in this filing.

Risks

• None identified in this filing.

Future Outlook

The company expects to grant the RSU and PSU awards on the first trading day of the first open window following the appointment date.

Industry Context

StockSavvy.ai notes that the appointment of an internal candidate to the Chief Accounting Officer role is a standard practice for mature public companies, signaling stability in financial reporting and internal controls.

Comparison to Industry Standards

• The compensation package is consistent with market standards for mid-to-large cap technology and healthcare services companies.
• The use of a mix of time-based RSUs and performance-based PSUs is a common governance practice to ensure executive alignment with long-term performance.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders benefit from continuity in financial leadership.
• Employees see clear internal career progression paths.

Next Steps

• Granting of RSU and PSU awards during the next open trading window.
• Vesting of RSU awards beginning August 15, 2026.
• Vesting of PSU awards beginning March 3, 2027.

Key Dates

Keywords

GoodRx, GDRX, Chief Accounting Officer, Corporate Governance, Executive Appointment, Financial Reporting